top border
top border
Featured Programs
PD-L1 Expression as a Biomarker in RCC
The panelists, Nizar M. Tannir, MD, FACP; Carlos H. Barrios, MD; Susanne Osanto, MD, PhD; Daniel Heng, MD, MPH, FRCPC; and Paul Nathan, MBBS, PhD, FRCP, address PD-L1 expression as a potential biomarker for selecting renal cell carcinoma (RCC) treatment. View Now

In this segment, Dean F. Bajorin, MD, and Evan Y. Yu, MD, discuss atezolizumab in muscle-invasive bladder cancer. View Now

 

Featured Video
Novel Combination Approaches for Metastatic Kidney Cancer
Brian Rini, MD, and David F. McDermott, MD, discuss novel combination approaches for patients with metastatic renal cell carcinoma. View now

Gina Columbus

Gina Columbus highlights the latest news in oncology in this week's OncLive News Network.

Publication Bottom Border
Border Publication
x